INCANNEX HEALTHCARE INC.

Press Releases Incannex Healthcare Inc.

Equities

IXHL

US45333F1093

Market Closed - Nasdaq Other stock markets 16:30:01 2024-05-24 EDT			5-day change	1st Jan Change
2.78 ^USD	+2.96%		+11.20%	-40.09%

05-07	Incannex Complete Successful Pre-Ind Meeting with the Fda for Cannquit-O for Treatment of Opioid Use Disorder	CI
03-05	Incannex Healthcare Inc. Announces CFO Changes	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder	05-07	AQ
Stonegate Healthcare Partners Releases Report on Potentially Transformative Therapies for Generalized Anxiety Disorder (GAD)	05-01	NE
Incannex Healthcare Inc. Quarterly Update, Q1 2024	04-16	AQ
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder	02-28	AQ
Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation	02-16	AQ
Clarion Clinics Open for Psychedelic-Assisted Treatments	02-01	AQ
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis	01-24	AQ
Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences	01-18	AQ
Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea	01-17	AQ
Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia	12-21	AQ
Incannex Healthcare : Change in Certifying Accountants - Form 8-K	12-15	PU
Incannex Update on IHL-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea	12-06	AQ
Incannex Appoints FDA Regulatory Affairs Expert Mr Robert B. Clark to the Board of Directors	22-08-17	GL
Incannex announces IHL-216A observed to have a neuroprotective effect in a rodent model of sports concussion; rapidly restores spatial memory post-concussion	22-05-10	PR
Incannex Completes Loyalty Option Program to Raise A$23.6M; Current Cash at Bank is Approximately A$40.0M	22-04-28	PR
Incannex to Acquire APIRx Pharmaceuticals USA, LLC	22-03-24	PR
Incannex observes substantial reduction in AHI in preliminary results of clinical trial assessing IHL-42X in patients with OSA; proceeds to pivotal studies	22-03-10	PR
Incannex Executes License Agreement with Monash University to Develop a Combination Treatment Using Virtual Reality and Psychedelics	22-03-03	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+201.5% on SUPER MICRO COMPUTER since our purchase on February 17, 2023

Replicate our performance

fermer